| 4.11 -0.03 (-0.72%) | 10-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.23 | 1-year : | 7.31 |
| Resists | First : | 5.33 | Second : | 6.26 |
| Pivot price | 4.38  |
|||
| Supports | First : | 3.83 | Second : | 3.19 |
| MAs | MA(5) : | 4.1  |
MA(20) : | 4.72 |
| MA(100) : | 4.93 |
MA(250) : | 5.01 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 17.2 |
D(3) : | 14.2 |
| RSI | RSI(14): 30.9 |
|||
| 52-week | High : | 7.44 | Low : | 3.15 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ZURA ] has closed above bottom band by 29.2%. Bollinger Bands are 0% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.37 - 4.39 | 4.39 - 4.41 |
| Low: | 4.01 - 4.05 | 4.05 - 4.07 |
| Close: | 4.07 - 4.11 | 4.11 - 4.15 |
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
Fri, 21 Aug 2026
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Tue, 18 Aug 2026
Zura Bio (NASDAQ: ZURA) director plans 50,000-share sale after prior trades - Stock Titan
Mon, 17 Aug 2026
Zura Bio (ZURA) Gains 1.97% to $5.68 as Shares Test Key Resistance at $5.96 - Parabolic SAR - careplusvn.com
Wed, 12 Aug 2026
Guggenheim raises Zura Bio stock price target on new drug indication - Investing.com
Tue, 11 Aug 2026
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates - BioSpace
Tue, 11 Aug 2026
Zura Bio Limited Stock 12‑Month Price Target Raised to $18.83, Implies 235% Upside - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 96 (M) |
| Shares Float | 51 (M) |
| Held by Insiders | 18.9 (%) |
| Held by Institutions | 87.8 (%) |
| Shares Short | 11,440 (K) |
| Shares Short P.Month | 10,250 (K) |
| EPS | -1.13 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.06 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -31.3 % |
| Return on Equity (ttm) | -51.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.97 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -78 (M) |
| Levered Free Cash Flow | -49 (M) |
| PE Ratio | -3.67 |
| PEG Ratio | 0 |
| Price to Book value | 1.98 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|